Aug 6 (Reuters) - Xenon Pharmaceuticals Inc XENE.O :
* XENON PHARMACEUTICALS REPORTS SECOND QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
* XENON PHARMACEUTICALS INC - XEN496 PHASE 3 PROTOCOL SUBMITTED TO FDA AND TRIAL INITIATION ANTICIPATED IN 2020
* XENON PHARMACEUTICALS INC - QTRLY LOSS PER SHARE $0.00
* XENON PHARMACEUTICALS INC - ANTICIPATES HAVING SUFFICIENT CASH TO FUND OPERATIONS INTO 2022